This study provides evidence that SGLT-2 inhibitors might offer clinically important benefits when provided in routine clinical practice compared with common alternative oral antidiabetic drugs that are added to metformin for people with type 2 diabetes mellitus. Here, SLC5A2 is linked to type 2 diabetes mellitus.